What does PEP PHARMA do?

PEP PHARMA is a pharmacy in Pepinster. Private Limited, started on 5 July 2010, 1 establishment.

What is the address of PEP PHARMA?

The registered office of PEP PHARMA is located at Rue Hubert Halet 5A/0, 4860 Pepinster.

Is PEP PHARMA still active?

Yes. According to the CBE (29 October 2026) PEP PHARMA is active, legal situation “Normale toestand”, started on 5 July 2010.

Is PEP PHARMA registered on Peppol?

Yes, PEP PHARMA is registered on the Peppol network with ID 0208:0827545996.

What is the enterprise number of PEP PHARMA?

The enterprise number of PEP PHARMA is BE0827545996.

When was PEP PHARMA founded?

PEP PHARMA was founded on 5 July 2010.

Who are the directors of PEP PHARMA?

According to the 2025 annual accounts, the directors of PEP PHARMA are: CECILE LELEUX, AC LELEUX.

Is PEP PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 July 2010; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PEP PHARMA make in 2025?

PEP PHARMA posted a profit after taxes of € 216,694 in financial year 2025.

What is the revenue of PEP PHARMA?

As a small company, PEP PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 326,063.

How much does an employee at PEP PHARMA earn?

The average wage cost per full-time employee at PEP PHARMA was € 43,500 in 2025: staff costs of € 69,553 for 1.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PEP PHARMA have?

According to the 2025 annual accounts, PEP PHARMA has 1.6 full-time equivalents (FTE).

PEP PHARMA (Private Limited) - Pepinster - BE0827545996

Dossier PEP PHARMA, printed on 29 October 2026 from databakkes.be/en/0827545996/pep-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 61 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PEP PHARMA from Pepinster, company number BE0827545996, closed financial year 2025 with a result of € 216,694 after tax. For that financial year PEP PHARMA recorded a gross margin of € 326,063 and equity of € 488,371. Compared with financial year 2024, the result moved from € 491,572 to € 216,694. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.

What it is worth Growing

€ 488,371

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 216,694

▼ 56% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 390,410

▲ 8% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 210,000 paid out

97 % of the profit went to the shareholders, mostly to A.C. LELEUX (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

1.6

▼ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 69,553

▲ 6% vs 2024

€ 43,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 37,914

▼ 13% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 36,228

▼ 44% vs 2024

€ 23,649 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 587,299

▲ 135% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 12,289

▼ 45% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 408,067 Gross margin 2022: € 408,067 First fiscal year in the series	€ 286,883 Gross margin 2023: € 286,883 ▼ 30% vs 2022 (€ 408,067) Unfavourable step	€ 614,611 Gross margin 2024: € 614,611 ▲ 114% vs 2023 (€ 286,883) Favourable step	€ 326,063 Gross margin 2025: € 326,063 ▼ 47% vs 2024 (€ 614,611) Unfavourable step	▼ 47%
Profit after taxes	€ 323,338 Profit after taxes 2022: € 323,338 First fiscal year in the series	€ 246,073 Profit after taxes 2023: € 246,073 ▼ 24% vs 2022 (€ 323,338) Unfavourable step	€ 491,572 Profit after taxes 2024: € 491,572 ▲ 100% vs 2023 (€ 246,073) Favourable step	€ 216,694 Profit after taxes 2025: € 216,694 ▼ 56% vs 2024 (€ 491,572) Unfavourable step	▼ 56%
Equity	€ 594,033 Equity 2022: € 594,033 First fiscal year in the series	€ 440,106 Equity 2023: € 440,106 ▼ 26% vs 2022 (€ 594,033) Unfavourable step	€ 481,678 Equity 2024: € 481,678 ▲ 9% vs 2023 (€ 440,106) Favourable step	€ 488,371 Equity 2025: € 488,371 ▲ 1% vs 2024 (€ 481,678) Favourable step	▲ 1%
Total debts	€ 239,433 Total debts 2022: € 239,433 First fiscal year in the series	€ 607,135 Total debts 2023: € 607,135 ▲ 154% vs 2022 (€ 239,433) Unfavourable step	€ 789,723 Total debts 2024: € 789,723 ▲ 30% vs 2023 (€ 607,135) Unfavourable step	€ 854,977 Total debts 2025: € 854,977 ▲ 8% vs 2024 (€ 789,723) Unfavourable step	▲ 8%
Cash	€ 552,353 Cash 2022: € 552,353 First fiscal year in the series	€ 544,067 Cash 2023: € 544,067 ▼ 2% vs 2022 (€ 552,353) Unfavourable step	€ 363,028 Cash 2024: € 363,028 ▼ 33% vs 2023 (€ 544,067) Unfavourable step	€ 390,410 Cash 2025: € 390,410 ▲ 8% vs 2024 (€ 363,028) Favourable step	▲ 8%
Retained profit	€ 340,033 Retained profit 2022: € 340,033 First fiscal year in the series	€ 186,106 Retained profit 2023: € 186,106 ▼ 45% vs 2022 (€ 340,033) Unfavourable step	€ 227,678 Retained profit 2024: € 227,678 ▲ 22% vs 2023 (€ 186,106) Favourable step	€ 234,371 Retained profit 2025: € 234,371 ▲ 3% vs 2024 (€ 227,678) Favourable step	▲ 3%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 400,000 Dividend 2023: € 400,000 Unchanged (€ 0) Unchanged	€ 450,000 Dividend 2024: € 450,000 ▲ 13% vs 2023 (€ 400,000) Unchanged	€ 210,000 Dividend 2025: € 210,000 ▼ 53% vs 2024 (€ 450,000) Unchanged	▼ 53%
Bank debt	€ 80,819 Bank debt 2022: € 80,819 First fiscal year in the series	€ 91,169 Bank debt 2023: € 91,169 ▲ 13% vs 2022 (€ 80,819) Unfavourable step	€ 64,256 Bank debt 2024: € 64,256 ▼ 30% vs 2023 (€ 91,169) Favourable step	€ 36,228 Bank debt 2025: € 36,228 ▼ 44% vs 2024 (€ 64,256) Favourable step	▼ 44%
Balance sheet total	€ 910,993 Balance sheet total 2022: € 910,993 First fiscal year in the series	€ 1,047,241 Balance sheet total 2023: € 1,047,241 ▲ 15% vs 2022 (€ 910,993) Unchanged	€ 1,271,401 Balance sheet total 2024: € 1,271,401 ▲ 21% vs 2023 (€ 1,047,241) Unchanged	€ 1,343,348 Balance sheet total 2025: € 1,343,348 ▲ 6% vs 2024 (€ 1,271,401) Unchanged	▲ 6%
Employees (FTE)	1.2 Employees (FTE) 2022: 1.2 First fiscal year in the series	2 Employees (FTE) 2023: 2 ▲ 0.8 vs 2022 (1.2) Unchanged	2.1 Employees (FTE) 2024: 2.1 ▲ 0.1 vs 2023 (2) Unchanged	1.6 Employees (FTE) 2025: 1.6 ▼ 0.5 vs 2024 (2.1) Unchanged	▼ 0.5

Key figures of PEP PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PEP PHARMA?

What happened at PEP PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 9, 2026 New annual accounts for financial year 2025: profit of € 216,694 (▼ 56% vs 2024). Source: NBB ↗
2018 CECILE LELEUX became a director. NBB
2018 AC LELEUX became a director. NBB
Jul 5, 2010 New establishment in Pepinster. KBO
Jul 5, 2010 Start of the company according to the CBE. KBO

In short

From € 323,338 profit in 2022 to € 216,694 profit in 2025.

Paid € 31,260 in corporate taxes since 2022.

Best year ever: 2024, with € 491,572 profit.

On average € 203,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

A.C. LELEUX 100%

The stake of A.C. LELEUX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PEP PHARMA

Behind PEP PHARMA are CECILE LELEUX and AC LELEUX. The shares are held by A.C. LELEUX (100%).

Directors

According to the 2025 annual accounts

CECILE LELEUX

Manager

Also active at: Union Pharmaceutique des Arrondissements Judiciaire de Verviers et Eupen, A.C. LELEUX

since 2018

AC LELEUX

Manager · represented by ANNE LELEUX

since 2018

Shareholders

A.C. LELEUX

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Hubert Halet 5A/0

4860 Pepinster

2.228.173.934

Rue Hubert Halet 5 box a/0

4860 Pepinster

Active since 5 July 2010

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PEP UNIT

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0827.545.996
VAT number: BE 0827.545.996
Registered office: Rue Hubert Halet 5A/0, 4860 Pepinster
Names & denominations: PEP PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 5 July 2010
Peppol: Active · Active since 3 Sept 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗